Epstein Secrets

f this report. Investors should consider this report as only a single factor in making their investment decision. EFTA00306883 Chris Schott. CFA North America Equity Research (1-212) 622-5676 02 June 2010 J.P.Morgan Investment Thesis, Valuation and Risks Merck & Co., Inc. (Overweight: Price Target: $64.00) Investment

erage universe. If it does not appear in the Ira runt Disclosures section of this report, the cettifying analyst's coverage universe can be found on M. Morgan's research website, Coverage Universe: Schott, Christopher: AbbVie (ABBV), Actavis plc (ACT), Allergan (AGN), Amarin Corporation (AMRN), Bristol-Mye

y-14 OW 57.11 64.00 4 EFTA00306886 Chris Schott. CFA North America Equity Research 1-21 622-5676 02 June 2014 J.P.Morgan The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire riot M. Morgan ratings or designations: OW -

18 O4 (Dec) 0.55 1.63 FY 2.05 5.61 6.52 7.54 Bloomberg EPS FY ($1 2.00 6.05 7.60 8.67 Source: Company On. Bloomberg. Morgan eabmates. North America Equity Research 22 May 2014 Overweight mum ►aces ua GILD, GILD US Price: $81.81 Price Target: $100.00 US Biotechnology AC Geoff Meacham Bloomberg JPMA AI

OW 72.67 85.00 18-0ec-13 OW 73.59 100.00 EFTA00300342 Coon Ktorerom North America Equity Research 22 May 2014 J.RMorgan The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period. J.P. Morgan ratings or designations:

n I/O compounds (GITR), BACE-inhibitor (Alzheimer's) and anaceptrapib (CETP), none of which appear to be reflected in Merck's current share price. North America Equity Research 02 October 2015 Pharmaceuticals — Major & Specialty Chris Schott, CFA AC (1-212)622-5676 Bloomberg JPMA SCHOTT <GO, Aditl Singhania, PhD (1-212

4 OW 57.11 64.00 10-Oct-14 OW 59.21 66.00 20-Jan-15 OW 63.03 68.00 21-Sep-15 OW 52.13 65.00 30-Sep-15 OW 49.39 66.00 The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire M. Morgan ratings or designations: OW Overwei